Carter Gould
Stock Analyst at Cantor Fitzgerald
(4.26)
# 1,448
Out of 4,704 analysts
643
Total ratings
54.7%
Success rate
6.9%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Maintained: Hold | $400 | $419.38 | -4.62% | 51 | Sep 8, 2026 | |
| LLY Eli Lilly and Company | Maintained: Buy | $1,350 → $1,410 | $1,183.16 | +19.17% | 101 | Aug 6, 2026 | |
| GILD Gilead Sciences | Maintained: Buy | $155 | $138.92 | +11.58% | 50 | Aug 4, 2026 | |
| PFE Pfizer | Maintained: Hold | $27 | $26.87 | +0.48% | 61 | Aug 4, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintained: Buy | $590 → $595 | $515.55 | +15.41% | 11 | Aug 4, 2026 | |
| ABBV AbbVie | Maintained: Buy | $265 → $285 | $250.33 | +13.85% | 50 | Jul 31, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintained: Hold | $54 → $59 | $64.63 | -8.71% | 36 | Jul 30, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintained: Buy | $750 → $795 | $805.93 | -1.36% | 53 | Jul 30, 2026 | |
| MRK Merck & Co. | Maintained: Hold | $120 | $135.97 | -11.75% | 44 | Mar 29, 2026 | |
| CYTK Cytokinetics | Maintained: Buy | n/a | $75.87 | - | 18 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $60.22 | n/a | 2 | Jun 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $209.15 | n/a | 45 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $63.53 | n/a | 24 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.14 | n/a | 16 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $23.01 | n/a | 14 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $9 | $1.53 | n/a | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $2.05 | n/a | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $160 | $154.49 | n/a | 29 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3 | $0.5935 | n/a | 9 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $160 | $225.95 | n/a | 1 | Jan 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $37 | $128.32 | n/a | 1 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | €80.32 | €136.40 | n/a | 1 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $82 → $86 | $123.50 | n/a | 4 | Jul 31, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $94 | $508.48 | n/a | 1 | May 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $16 → $4 | $2.53 | n/a | 2 | Feb 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $6 → $2.8 | $9.18 | n/a | 2 | Jan 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 → $13 | $0.89 | n/a | 2 | Nov 12, 2018 |
Amgen
Sep 8, 2026
Maintained: Hold
Price Target: $400
Current: $419.38
Upside: -4.62%
Eli Lilly and Company
Aug 6, 2026
Maintained: Buy
Price Target: $1,350 → $1,410
Current: $1,183.16
Upside: +19.17%
Gilead Sciences
Aug 4, 2026
Maintained: Buy
Price Target: $155
Current: $138.92
Upside: +11.58%
Pfizer
Aug 4, 2026
Maintained: Hold
Price Target: $27
Current: $26.87
Upside: +0.48%
Vertex Pharmaceuticals
Aug 4, 2026
Maintained: Buy
Price Target: $590 → $595
Current: $515.55
Upside: +15.41%
AbbVie
Jul 31, 2026
Maintained: Buy
Price Target: $265 → $285
Current: $250.33
Upside: +13.85%
Bristol-Myers Squibb Company
Jul 30, 2026
Maintained: Hold
Price Target: $54 → $59
Current: $64.63
Upside: -8.71%
Regeneron Pharmaceuticals
Jul 30, 2026
Maintained: Buy
Price Target: $750 → $795
Current: $805.93
Upside: -1.36%
Merck & Co.
Mar 29, 2026
Maintained: Hold
Price Target: $120
Current: $135.97
Upside: -11.75%
Cytokinetics
Feb 25, 2026
Maintained: Buy
Price Target: n/a
Current: $75.87
Upside: -
Jun 10, 2025
Reiterated: Buy
Price Target: n/a
Current: $60.22
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $209.15
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $63.53
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $0.14
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $23.01
Upside: n/a
Nov 8, 2024
Rated: Buy
Price Target: $9
Current: $1.53
Upside: n/a
Nov 7, 2024
Maintained: Buy
Price Target: $12
Current: $2.05
Upside: n/a
Oct 31, 2024
Maintained: Buy
Price Target: $160
Current: $154.49
Upside: n/a
Aug 14, 2024
Maintained: Buy
Price Target: $3
Current: $0.5935
Upside: n/a
Jan 11, 2023
Rated: Hold
Price Target: $160
Current: $225.95
Upside: n/a
Dec 7, 2022
Initiated Coverage: Buy
Price Target: $37
Current: $128.32
Upside: n/a
Feb 27, 2020
Initiated Coverage: Buy
Price Target: €80.32
Current: €136.40
Upside: n/a
Jul 31, 2019
Maintained: Hold
Price Target: $82 → $86
Current: $123.50
Upside: n/a
May 17, 2019
Upgraded: Hold
Price Target: $94
Current: $508.48
Upside: n/a
Feb 1, 2019
Downgraded: Hold
Price Target: $16 → $4
Current: $2.53
Upside: n/a
Jan 11, 2019
Maintained: Hold
Price Target: $6 → $2.8
Current: $9.18
Upside: n/a
Nov 12, 2018
Maintained: Buy
Price Target: $18 → $13
Current: $0.89
Upside: n/a